Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
42
QURE Quote, Financials, Valuation and Earnings
Last price:
$17.05
Seasonality move
:
8.01%
Day range:
$15.35 - $17.58
52-week range:
$3.73 - $17.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
28.74x
P/B ratio:
14.83x
Volume:
2.1M
Avg. volume:
3.4M
1-year change:
172.33%
Market cap:
$827.7M
Revenue:
$15.8M
EPS (TTM):
-$4.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$7.1M | -$1.01 | 194.09% | -62.87% | $30.72 |
|
ARGX
argenx SE
|
$539.9M | $0.06 | 62.39% | -44.75% | $655.15 |
|
MRUS
Merus NV
|
$8.7M | -$0.85 | -4.27% | -10.77% | $86.07 |
|
PHAR
Pharming Group
|
$76M | -$0.00 | 0.91% | -- | -- |
|
PHVS
Pharvaris NV
|
-- | -$0.66 | -- | -6.9% | -- |
|
PRQR
ProQR Therapeutics NV
|
$12.3M | -$0.14 | 25.16% | -54.98% | $4.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$16.98 | $30.72 | $827.7M | -- | $0.00 | 0% | 28.74x |
|
ARGX
argenx SE
|
$623.82 | $655.15 | $37.3B | -- | $0.00 | 0% | 20.45x |
|
MRUS
Merus NV
|
$41.87 | $86.07 | $2.9B | -- | $0.00 | 0% | 71.67x |
|
PHAR
Pharming Group
|
$9.10 | -- | $617.3M | -- | $0.00 | 0% | 2.36x |
|
PHVS
Pharvaris NV
|
$19.99 | -- | $1.1B | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$2.66 | $4.10 | $281.2M | -- | $0.00 | 0% | 11.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QURE
uniQure NV
|
47.8% | 0.153 | 21.27% | 6.18x |
|
ARGX
argenx SE
|
-- | -0.253 | -- | 7.52x |
|
MRUS
Merus NV
|
-- | 1.520 | -- | 7.94x |
|
PHAR
Pharming Group
|
29.71% | -1.043 | 17.05% | 2.76x |
|
PHVS
Pharvaris NV
|
-- | -2.127 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
15.29% | -1.974 | 3.39% | 2.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
|
ARGX
argenx SE
|
$514.2M | $16.2M | -5.47% | -6.01% | 15.47% | -$147M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
PHAR
Pharming Group
|
$68M | $4.1M | -5.33% | -8.24% | 6.03% | $9.4M |
|
PHVS
Pharvaris NV
|
-- | -$41.7M | -- | -- | -- | -$38.1M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$9.7M | -59.09% | -66.59% | -230.39% | -$7.1M |
uniQure NV vs. Competitors
-
Which has Higher Returns QURE or ARGX?
argenx SE has a net margin of -1940.45% compared to uniQure NV's net margin of 15.95%. uniQure NV's return on equity of -154.29% beat argenx SE's return on equity of -6.01%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M ARGXargenx SE89.7% $1.39 $4.3B -
What do Analysts Say About QURE or ARGX?
uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 80.94%. On the other hand argenx SE has an analysts' consensus of $655.15 which suggests that it could grow by 5.02%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 ARGXargenx SE13 2 0 -
Is QURE or ARGX More Risky?
uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison argenx SE has a beta of 0.589, suggesting its less volatile than the S&P 500 by 41.058%.
-
Which is a Better Dividend Stock QURE or ARGX?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or ARGX?
uniQure NV quarterly revenues are $2.3M, which are smaller than argenx SE quarterly revenues of $573.2M. uniQure NV's net income of -$44.4M is lower than argenx SE's net income of $91.4M. Notably, uniQure NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 28.74x versus 20.45x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV28.74x -- $2.3M -$44.4M ARGXargenx SE20.45x -- $573.2M $91.4M
-
Which has Higher Returns QURE or MRUS?
Merus NV has a net margin of -1940.45% compared to uniQure NV's net margin of -848.67%. uniQure NV's return on equity of -154.29% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About QURE or MRUS?
uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 80.94%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 105.57%. Given that Merus NV has higher upside potential than uniQure NV, analysts believe Merus NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 MRUSMerus NV12 0 0 -
Is QURE or MRUS More Risky?
uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Merus NV has a beta of 1.071, suggesting its more volatile than the S&P 500 by 7.125%.
-
Which is a Better Dividend Stock QURE or MRUS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or MRUS?
uniQure NV quarterly revenues are $2.3M, which are smaller than Merus NV quarterly revenues of $11.8M. uniQure NV's net income of -$44.4M is higher than Merus NV's net income of -$99.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 28.74x versus 71.67x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV28.74x -- $2.3M -$44.4M MRUSMerus NV71.67x -- $11.8M -$99.9M
-
Which has Higher Returns QURE or PHAR?
Pharming Group has a net margin of -1940.45% compared to uniQure NV's net margin of -1.38%. uniQure NV's return on equity of -154.29% beat Pharming Group's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PHARPharming Group90.89% -$0.02 $321.2M -
What do Analysts Say About QURE or PHAR?
uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 80.94%. On the other hand Pharming Group has an analysts' consensus of -- which suggests that it could grow by 196.7%. Given that Pharming Group has higher upside potential than uniQure NV, analysts believe Pharming Group is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PHARPharming Group0 0 0 -
Is QURE or PHAR More Risky?
uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHAR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHAR?
uniQure NV quarterly revenues are $2.3M, which are smaller than Pharming Group quarterly revenues of $74.8M. uniQure NV's net income of -$44.4M is lower than Pharming Group's net income of -$1M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 28.74x versus 2.36x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV28.74x -- $2.3M -$44.4M PHARPharming Group2.36x -- $74.8M -$1M
-
Which has Higher Returns QURE or PHVS?
Pharvaris NV has a net margin of -1940.45% compared to uniQure NV's net margin of --. uniQure NV's return on equity of -154.29% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PHVSPharvaris NV-- -$0.85 -- -
What do Analysts Say About QURE or PHVS?
uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 80.94%. On the other hand Pharvaris NV has an analysts' consensus of -- which suggests that it could grow by 72.95%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PHVSPharvaris NV0 0 0 -
Is QURE or PHVS More Risky?
uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHVS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHVS?
uniQure NV quarterly revenues are $2.3M, which are larger than Pharvaris NV quarterly revenues of --. uniQure NV's net income of -$44.4M is higher than Pharvaris NV's net income of -$45.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 28.74x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV28.74x -- $2.3M -$44.4M PHVSPharvaris NV-- -- -- -$45.9M
-
Which has Higher Returns QURE or PRQR?
ProQR Therapeutics NV has a net margin of -1940.45% compared to uniQure NV's net margin of -210.98%. uniQure NV's return on equity of -154.29% beat ProQR Therapeutics NV's return on equity of -66.59%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PRQRProQR Therapeutics NV-- -$0.11 $32.9M -
What do Analysts Say About QURE or PRQR?
uniQure NV has a consensus price target of $30.72, signalling upside risk potential of 80.94%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $4.10 which suggests that it could grow by 201.32%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PRQRProQR Therapeutics NV2 1 0 -
Is QURE or PRQR More Risky?
uniQure NV has a beta of 0.895, which suggesting that the stock is 10.539% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.240, suggesting its less volatile than the S&P 500 by 75.965%.
-
Which is a Better Dividend Stock QURE or PRQR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PRQR?
uniQure NV quarterly revenues are $2.3M, which are smaller than ProQR Therapeutics NV quarterly revenues of $4.2M. uniQure NV's net income of -$44.4M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, uniQure NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 28.74x versus 11.17x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV28.74x -- $2.3M -$44.4M PRQRProQR Therapeutics NV11.17x -- $4.2M -$8.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
